Swedbank AB Sells 259,245 Shares of Edwards Lifesciences Co. (NYSE:EW)

Swedbank AB lessened its holdings in Edwards Lifesciences Co. (NYSE:EW) by 21.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 969,512 shares of the medical research company’s stock after selling 259,245 shares during the quarter. Swedbank AB owned 0.16% of Edwards Lifesciences worth $63,978,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in EW. Park Avenue Securities LLC increased its holdings in shares of Edwards Lifesciences by 0.5% in the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after buying an additional 108 shares during the period. City State Bank increased its stake in Edwards Lifesciences by 16.5% in the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after purchasing an additional 130 shares during the period. Stableford Capital II LLC lifted its position in Edwards Lifesciences by 2.7% in the second quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock valued at $533,000 after purchasing an additional 159 shares during the last quarter. Purus Wealth Management LLC boosted its stake in shares of Edwards Lifesciences by 5.2% during the second quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock valued at $297,000 after purchasing an additional 160 shares during the period. Finally, Busey Bank grew its holdings in shares of Edwards Lifesciences by 1.9% in the second quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock worth $816,000 after purchasing an additional 165 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Citigroup lowered their price target on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a report on Tuesday, October 1st. Truist Financial dropped their target price on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a report on Friday, October 25th. Wells Fargo & Company reduced their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Finally, Oppenheimer reissued an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and a consensus target price of $75.67.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,000 shares of company stock worth $2,657,000. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 0.1 %

EW stock opened at $70.48 on Monday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business has a 50 day moving average of $67.70 and a 200 day moving average of $75.59. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The firm has a market cap of $41.57 billion, a PE ratio of 10.17, a price-to-earnings-growth ratio of 3.96 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the firm earned $0.59 EPS. Edwards Lifesciences’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.